Drug Trial Radar · NCT01725087
Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.
Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,089
Actual
Start
Nov 2012
Primary completion
Jul 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Forest Laboratories
- First posted
- Nov 12, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate the safety and efficacy of once daily orally administered GRT6005 in a total of 3 fixed doses compared to placebo in subjects with moderate to severe chronic Low Back Pain (LBP). The study includes a maximum of 21 days screening period followed by a 2-week titration period and 12-week maintenance double-blind treatment period and a 10-14 day safety follow up period. Patients who are eligible for the double-blind treatment period will be randomized to one of the following treatment groups: GRT6005 low-dose, GRT6005 medium dose, GRT6005 high-dose, Tapentadol or placebo.
Conditions
- Low Back Pain
Interventions
Matching PlaceboDrug
Low Dose GRT6005Drug
Medium Dose GRT6005Drug
High Dose GRT6005Drug
TapentadolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- European Union: the change from baseline pain to the weekly average 24-hour pain during the entire 12 weeks of the maintenance phase of the double-blind Treatment Period.Time frame: Baseline to End of Treatment (Week 14)
- United States: the change from baseline pain to the average 24-hour pain during Week 12 of the maintenance phase.Time frame: Baseline to End of Treatment (Week 14)
Locations
79 sites in 11 countries. Site status is shown where the registry gives one.
AT003
Senftenberg, Austria
AT004
Vienna, Austria
AT001
Vienna, Austria
AT005
Vienna, Austria
AT006
Vienna, Austria
BE001
Brussels, Belgium
BE002
Edegem, Belgium
BE004
Genk, Belgium
DK004
Aalborg, Denmark
DK001
Frederiksberg, Denmark
Site DK002
Glostrup Municipality, Denmark
DK003
Odense, Denmark
FI005
Kokkola, Finland
FI001
Kuopio, Finland
FI003
Lahti, Finland
DE005
Bad Nauheim, Germany
DE014
Berlin, Germany
DE018
Berlin, Germany
DE011
Bochum, Germany
DE015
Böhlen, Germany
DE007
Dresden, Germany
DE016
Essen, Germany
DE001
Hamburg, Germany
DE006
Hamburg, Germany
DE008
Hanover, Germany
DE002
Leipzig, Germany
DE019
Leipzig, Germany
DE009
Mosbach, Germany
DE004
Munich, Germany
DE013
Rodgau, Germany
DE017
Wiesbaden, Germany
HU010
Baja, Hungary
HU008
Békéscsaba, Hungary
HU011
Budapest, Hungary
HU015
Budapest, Hungary
HU005
Budapest, Hungary
HU012
Budapest, Hungary
HU003
Kecskemét, Hungary
HU002
Kiskunfélegyháza, Hungary
HU001
Makó, Hungary
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.